This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ensign Group Pays $48 Million To Settle Whistleblower Lawsuits Alleging Medicare Billing Fraud

LOS ANGELES, Nov. 19, 2013 /PRNewswire/ -- A whistleblower lawsuit brought by Phillips & Cohen LLP was the primary basis for a $48 million settlement the federal government announced today with the Ensign Group involving Medicare billing fraud.

The "qui tam" (whistleblower) lawsuit alleged skilled nursing facilities operated by Ensign subsidiaries were billing Medicare for treatment of patients that wasn't actually provided or wasn't medically necessary. The government also alleged that some patients were admitted for treatment at the nursing homes when they didn't need to be and that some were kept in the facilities longer than was medically necessary.

"The culture of the company emphasized profits over compliance and patient needs," said Larry P. Zoglin, a San Francisco whistleblower attorney who is Of Counsel with Phillips & Cohen (

Each facility administrator was required by company management to set what were called "Big Hairy Audacious Goals" for the number of Medicare patients and the amount of Medicare reimbursement per day, according to the whistleblower complaint. When goals were reached, administrators were rewarded with benefits such as all-expense paid trips to Hawaii, Alaska and other vacation spots.

"The goals that administrators were required to set were 'audacious' -- not because they were overly optimistic but because the company was pressuring administrators to achieve goals that realistically could be met only by cheating Medicare," attorney Zoglin said.

One way that managers met their "audacious" goals was to offer incentives to rehabilitation therapists and others to achieve high Medicare revenue targets, which the therapists could do only by billing at higher rates than was justified or by extending rehab therapy for longer periods than the patients needed, according to the settlement agreement.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs